Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels.

	Organisation	Precirix N.V.
	Organisation 2	Chord Therapeutics S.A.
	Group	Merck (DE) (Group)
	Product	RADIOPHARMACEUTICAL (RPT)
	Product 2	drug development
	Person	Plitz, Thomas (Tom) (Chord Therapeutics 202010 CEO before CSO at Wilson Therapeutics)
	Person 2	Devenyns, Ruth (Precirix 202009 CEO formerly KBC 200910 KBC Private Equity)

Precirix, a biotechnology company developing precision radiopharmaceuticals in oncology, today announces that Tom Plitz has been appointed CEO of the company. Former CEO, Ruth Devenyns, will remain in an advisory role for the next month to ensure a smooth transition. The company is furthermore reinforcing its team of experts and received additional financial support from its investors to drive CAM-FAP towards the clinic and define the clinical development plan of CAM-H2.

Tom Plitz brings a wealth of experience, combining a strong R&D background with entrepreneurial experience and strong leadership skills. Most recently he was the CEO of Chord Therapeutics, a clinical stage biotech company active in neurology which was sold to Merck. Before that he served as CSO of Wilson Therapeutics acquired by Alexion. Earlier in his career he worked in several pharma companies in R&D roles with increasing responsibilities.

Using camelid single-domain antibodies as carrier molecules, Precirix has developed a strong expertise in precision radiopharmaceuticals, working with different isotopes allowing for a theranostic approach. Precirix is now driving its FAP-targeting compound towards clinical readiness. CAM-FAP has demonstrated strong pre-clinical results and passed extensive IND-enabling tox studies. CMC activities are fully ongoing to support IND submission. CAM-H2, a single-domain antibody targeting HER2 combined with iodine-131, recently completed a Phase I clinical study where it demonstrated safety and specific targeting of cancer cells. Precirix is supported by a strong SAB and other external experts with long-standing industry experience.

Tom Plitz commented: “I am excited to begin my journey with Precirix and thank the Board for their confidence. Precirix has developed a strong expertise in the field of precision radiopharmaceuticals and their CMC, allowing them to progress their novel single-domain antibody-radiotherapeutics into the clinic. Together with the team I look forward to further build on this foundation to promote medical innovation and improve human health.”

Simon Sturge, Chairman of the board, commented: “We are delighted to onboard Tom Plitz as CEO. Tom has the right background to further strengthen our R&D platform and progress our compounds towards clinical development. I want to thank former CEO Ruth Devenyns for building the company’s foundation and wish her the best of luck in her future endeavors.”

About Precirix

Precirix is a private biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labeled with radioisotopes. CAM-H2, a HER2-directed sdAb combined with iodine-131 recently completed a Phase I clinical study. The company’s Fibroblast Activation Protein (FAP)-targeting program is transitioning into the clinic. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology allows for a theranostic approach, where patients can be selected using an imaging version of the product, followed by a therapeutic dose for treatment.

Record changed: 2024-03-27